Background: Emerging evidence suggests that implant therapy may be a viable option for diabetic individuals with elevated glycemic levels.
INTRODUCTION
Diabetes mellitus, a chronic metabolic disorder affecting over 20 million individuals, or 8.5% of the U.S. adult population, is considered one of the most commonly encountered contraindications to dental implant therapy. 1, 2 As a result, well-controlled diabetic individuals are often considered appropriate for implant therapy while those lacking good glycemic control may be denied the benefits of implant therapy.
control, did not clearly assess or report glycemic levels, limiting their applicability toward clinical practice. The remaining four identified studies had documentation of glycemic levels using HbA1c and reported a narrower range of implant failure rates (0 to 9.1%) and individuals experiencing implant failure (0 to 4.1%). [12] [13] [14] [15] Only one of these studies extended beyond 1 year, and this study evaluated just one individual with an elevated HbA1c over 9%. 13 This study found no significant difference comparing the overall non-diabetic group survival rate (98.8%) and the diabetic group survival rate (97.2%). A more recent cohort study included 117 individuals with and without type 2 diabetes. This study failed to identify any increased risk for implant failure after 1 year in function. 16 However, this study relied on edentulous individuals receiving two mandibular implants supporting removable dental prostheses, for individuals with a wide range of glycemic control.
It is these individuals with poor glycemic control that may have an enhanced vulnerable to implantrelated biologic complications consistent with their increased vulnerability to periodontal disease. [17] [18] [19] [20] However, the evidence for increased risk of periimplant disease with poor glycemic control remains limited. [21] [22] [23] [24] Therefore, purpose of this study was to extend the observational period following a 4 month comparative trial of dental implant therapy for this unique group of poorly-controlled type 2 diabetic individuals to examine the potential for poor glycemic control to compromise implant performance, including biologic complications and implant failures, after 2 years.
MATERIALS AND METHODS
This observational, cohort study is a long-term follow-up of participants with poorly-controlled type 2 diabetes mellitus that received dental implants as part of a randomized comparative study of implant surfaces (NCT01142297). 15 [Zila, Inc., Phoenix, AZ, USA]) for 7-14 days. After a minimum of 16 weeks of healing, the participants received implant-supported fixed dental prostheses. Maintenance was offered by providers outside of the study and was not required for participants to remain in this study. A total of 72 implants were placed in these 24 participants between March 2009 and January 2010 ( Figure 1 ). All implants were solid, onepiece implants of 8 mm or 10 mm in length with a 1.8 mm polished collar. Participants were seen 13 to 16 months after implant placement to evaluate implant complications and HbA1c levels, and were then recalled for a long-term follow-up which occurred between 21 and 34 months post-surgery to assess implant survival and success by a single examiner. During follow-up visits, medical history was reviewed. Any adverse event or symptom related to implant treatment was recorded, and signs or symptoms of clinical complications were noted. Survival was defined as the implant remaining in situ throughout the observation period. Implant evaluation included each of the following: implant stability (as detected by sound on percussion or by visual/tactile evidence), pain, peri-implant mucositis (presenting as bleeding and/or suppuration on light probing), and radiographic findings (i.e., peri-implant radiolucencies or clinically-evident changes in crestal bone loss of 2 mm). Peri-implantitis was diagnosed if periimplant mucositis existed in combination with signs of crestal bone loss occurring after the 4 month healing period to allow for osseous remodeling following surgical placement. Additional adverse events or restorative complications were noted, such as prosthetic material fracture or screw loosening. [25] [26] [27] Correlations between HbA1c levels and the ratio of complications/number of implant were determined using Pearson's correlation with the HbA1c levels for both the average HbA1c during the 4-month comparative study and the value at the 2 year visit stratified using 1% increments. The overall ratio of complications and the ratio of cases of mucositis were determined relative to the number of implants placed within each stratification group.
RESULTS
At the 1-year clinical evaluation, 23 of the 24 participants returned, representing a total of 70 of the original 72 implants placed. Of the 70 implants evaluated, 69 (98.6%) implants survived through the first year. The one implant failure was an early failure, occurring between weeks 4 and 6 following implant placement. This implant was successfully replaced and restored without further complications, and was evaluated at the 1 and 2 year assessments. Most conservatively assuming the two implants on the one participant who did not return for the 1-year evaluation were failures, the implant survival after 1 year was 95.8%.
Twenty of the initial 24 participants, with 59 implants, were evaluated for survival after 2 years. Of the 59 implants evaluated, 58 implants survived through 2 years. These implants represent 58 of the 60 (96.7%) implants originally placed, including the one early failure that was replaced successfully.
The 20 returning participants included 7 males and 13 females with an average age of 59.9 years. At the time of the 2-year follow-up, HbA1c levels were between 6.3% and 13.1%, with a mean value of 8.9 6 2.0%. This mean HbA1c level had decreased from the baseline level of 9.70 6 0.83% (Table 1) . Twelve participants had HbA1c values at this longterm evaluation visit that decreased from their initial levels, with 9 of these 12 participants showing decreased HbA1c of more than 1%. Five participants had increased HbA1c levels, with two having an increase 1%.
Clinically, all but two implants evaluated over the course of the study survived (Table 2 ). In addition to the one early implant failure noted above, one implant was lost after 31 months (26 months postrestoration). This participant reported pain on chewing for 4 weeks, and on evaluation the implant exhibited mobility and radiographic bone loss circumferentially (Figure 2 ). This participant had four additional implants placed and restored as part of the study, including two in the posterior maxilla and two in the posterior mandible, all of which showed no signs of clinical complications over this time period.
Assessment of complications after 2 years was completed on 18 of these 20 participants, representing 52 implants, with a mean follow-up time of 28.0 6 3.8 months after implant placement (Figure 1 ). The four participants not included in the 2 year follow-up were unable to be contacted or declined further participation, with two others not completing the clinical evaluation for complications, but no participants reported any implant-related complications.
In the 18 participants with 52 implants, 15 biologic complications (29.4% of implants) were encountered during the course of the long-term follow-up, with the most frequent being peri-implant mucositis (21.6% of implants). While the total number of implants per HbA1c category was positively correlated with number of complications (0.42, R 2 5 0.66), there were minimal correlations between HbA1c levels and the percentages of implants with number of complications (20.028, R 2 5 0.11) or occurrences of mucositis (20.026, R 2 5 0.09; Figures 3 and 4) .
Ten of the 18 participants experienced a biologic complication on at least one implant. The majority of implants showed no signs of bone loss, peri-implant mucositis, or restorative complications ( Table 3 ). The participants required no additional treatment other than standard maintenance procedures to address these complications. The most common adverse event was mild to moderate soft tissue inflammation, or peri-implant mucositis, identified through demonstration of bleeding on probing (11 implants in 8 subjects; Table 3 ). Additional adverse events included gingival hyperplasia (2 implants in 1 subject), gingival recession (1 implant), and radiographic peri-implant crestal bone loss (3 implants in 2 subjects). The crestal bone loss was seen to the level of the first thread of the implants. However, the bone loss seen on all three of these implants was consistent with that evident in radiographs of these implants taken 4 months after placement, suggesting that the bone loss occurred during the first few months following placement and with little change over the following 2 years. Additionally, no signs of gingival inflammation, as suggestive of peri-implantitis, were seen around these implants, and stability of the implants had not been affected.
DISCUSSION
The goal of this study was to extend our understanding of the relationship between glycemic control for individuals with type 2 diabetes and dental implant therapy. This group of poorly-controlled diabetic participants with glycated hemoglobin levels as high as 13.1% was re-evaluated at an intermediate time point approximately 1 year following implant placement and again 2 years after implant placement. While this study had 25% attrition over the 2-year period, there were minimal differences in the participant characteristic between the participants seen versus those lost to follow-up, offering a valuable perspective on a unique group of individuals with type 2 diabetes receiving dental implants. Evaluation of implant-related outcomes over this 2-year period is important as there is little direct information available in the literature to guide this process. In considering the value in examining the effects of elevated glycemic levels over a longer time period as done in this study, it must be remembered that the majority of individuals with diabetes lack good glycemic control. In fact, it has been reported that as many as 60% of type 2 diabetes individuals under physician care have HbA1c levels greater than 8%, and 39% of US diabetes individuals were reported as having HbA1c levels over 10%. 28, 29 In this light, the use of glycemic levels to determine the appropriateness of implant therapy relative to the benefits derived from this treatment must be considered carefully.
There is no doubt that these elevated glycemic levels are directly associated with increased risk of numerous systemic co-morbidities, including periodontal disease. Given the documented risks of diabetic subjects for inflammatory periodontal disease, compromised wound healing, and infection, the potential for long-term peri-implant complications may represent a similar vulnerability. [30] [31] [32] [33] [34] Previous studies have shown that glycemic control can affect bone physiology, and impaired osseous healing has been demonstrated in animal models. [4] [5] [6] [7] [8] [9] These studies also suggest concerns with establishing and maintaining the health of the supporting tissues for implants. Importantly, this observational study documented little relationship between glycemic levels and implant-related clinical complications for type 2 diabetes patients having mean glycemic levels (HbA1c) between 6.3% and 13.1% over 2 years after implant placement, and above 8% at the time of implant placement. These findings reinforce recent examinations of the literature questioning our understanding of the role of glycemic control as a risk factor for implant failure along with a recent 1-year prospective study.
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Figure 4 Peri-mucositis: Number of implants identified with peri-mucositis and the total number of implants evaluated in relation to stratified HbA1c (%) values as measured at the 2-year follow-up visit. The findings from this study begin to offer some clarity to the deficiencies documented in previous reports in the literature (for review see Oates 2012).
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The 96.2% survival rate found after 2 years in this study is consistent with previous reports of implants in non-diabetic subjects. A recent review of the literature identified five previous studies that directly compared failure rates between diabetic and non-diabetic individuals, with none of these studies finding a significant difference in implant survival for diabetic individuals. 35 The success rates in these studies ranged from 92.2 to 100% for diabetic individuals and 93.2 to 100% for non-diabetic individuals.
In the current study, one implant failed during the integration phase, and one implant failed 31 months after placement, giving a cumulative survival rate of 96.2% for all implants. Interestingly, at the time of this 31-month failure, the participant's HbA1c was 12.4%, whereas his mean HbA1c throughout the observational period was 10.5%. This difference highlights the inconsistencies in glycemic control in many diabetic subjects with poor control, and may suggest a more subtle relationship between glycemic levels and inflammatory conditions. While the patient did experience one implant failure, he had four successful implants as well, suggesting that local factors rather than systemic factors may have had a contribution to the failure.
Although our knowledge of the ways in which HbA1c values effect implant osseointegration are limited, this study demonstrates the potential for implants to be a successful treatment option for poorly controlled diabetic patients within the clinical conditions provided within this study design. This study protocol did include the use of postoperative antibiotics, an oral antimicrobial rinse, and an extended integration period prior to restoration. The value of these modifications individually or collectively cannot be determined from the current investigation, but may form the basis for further study. Additionally, these patients did not participate in a structured maintenance program. Given the positive outcomes of the study, this reinforces the applicability of the findings to a broader group of patients.
Understanding the potential for successful implant therapy independent of glycemic control may be critical in supporting the overall management of individuals' oral health. The findings of biologic complications at a frequency of 29.4%, with the most frequent being periimplant mucositis, are consistent with reports in the literature for non-diabetic patients. 36 Numerous studies have shown that patients with diabetes have a significantly increased risk of periodontal disease with resultant tooth loss. 18, 24, 37 The risks of partial or complete edentulism in the diabetic population is of concern because it may affect the individual's ability to maintain a healthy diet due to a decreased chewing efficiency. These compromises in diet may have a negative impact on glycemic control. 38, 39 Ultimately, these patients may benefit from tooth replacement, and the appropriate application of implant therapy may become an important contribution to the health and wellbeing of diabetic patients looking to improve glycemic control.
In conclusion, this study evaluated dental implants for a small but unique group of individuals with poorly controlled diabetes after a 2-year period. While the impact of glycemic levels on long-term dental implant therapy remains in question, this study demonstrates encouraging results in building our understanding of implant therapy among our treatment options for these patients. As we continue to clarify both the risks and benefits of implant therapy for patients with diabetes, long-term longitudinal studies with large sample sizes will be necessary to confirm the results of the present study. We look forward to clarifying the role of the dental care for these patients in the future.
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